A detailed history of Macquarie Group LTD transactions in Immunovant, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 122,100 shares of IMVT stock, worth $3.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
122,100
Previous 103,100 18.43%
Holding current value
$3.36 Million
Previous $3.33 Million 3.24%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$25.1 - $31.61 $476,900 - $600,590
19,000 Added 18.43%
122,100 $3.22 Million
Q1 2024

May 14, 2024

BUY
$30.27 - $43.79 $1.89 Million - $2.74 Million
62,474 Added 153.78%
103,100 $3.33 Million
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $1.27 Million - $1.8 Million
40,626 New
40,626 $1.71 Million
Q3 2022

Nov 14, 2022

SELL
$3.93 - $6.37 $3,839 - $6,223
-977 Reduced 80.08%
243 $7,000
Q4 2021

Feb 11, 2022

SELL
$7.33 - $9.32 $20,545 - $26,123
-2,803 Reduced 69.67%
1,220 $10,000
Q3 2021

Nov 12, 2021

SELL
$7.01 - $11.37 $352,960 - $572,490
-50,351 Reduced 92.6%
4,023 $35,000
Q2 2021

Aug 13, 2021

BUY
$9.4 - $16.85 $31,339 - $56,177
3,334 Added 6.53%
54,374 $575,000
Q1 2021

May 14, 2021

BUY
$13.08 - $49.6 $392,138 - $1.49 Million
29,980 Added 142.36%
51,040 $819,000
Q4 2020

Feb 16, 2021

SELL
$36.36 - $52.71 $58,103 - $84,230
-1,598 Reduced 7.05%
21,060 $973,000
Q3 2020

Nov 13, 2020

BUY
$22.61 - $38.9 $491,925 - $846,347
21,757 Added 2414.76%
22,658 $798,000
Q2 2020

Aug 11, 2020

SELL
$13.87 - $28.44 $31,998 - $65,611
-2,307 Reduced 71.91%
901 $22,000
Q1 2020

May 15, 2020

BUY
$8.36 - $17.13 $26,818 - $54,953
3,208 New
3,208 $50,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.